@article{2119b21f38524d50a84aeeb8b761b2d7,
title = "Synthesis and Structural Characterization of Ricin Inhibitors Targeting Ribosome Binding Using Fragment-Based Methods and Structure-Based Design",
abstract = "Ricin toxin A subunit (RTA) is the catalytic subunit of ricin, which depurinates an adenine from the sarcin/ricin loop in eukaryotic ribosomes. There are no approved inhibitors against ricin. We used a new strategy to disrupt RTA-ribosome interactions by fragment screening using surface plasmon resonance. Here, using a structure-guided approach, we improved the affinity and inhibitory activity of small-molecular-weight lead compounds and obtained improved compounds with over an order of magnitude higher efficiency. Four advanced compounds were characterized by X-ray crystallography. They bind at the RTA-ribosome binding site as the original compound but in a distinctive manner. These inhibitors bind remotely from the catalytic site and cause local conformational changes with no alteration of the catalytic site geometry. Yet they inhibit depurination by ricin holotoxin and inhibit the cytotoxicity of ricin in mammalian cells. They are the first agents that protect against ricin holotoxin by acting directly on RTA.",
author = "Li, {Xiao Ping} and Harijan, {Rajesh K.} and Bin Cao and Kahn, {Jennifer N.} and Michael Pierce and Tsymbal, {Anastasiia M.} and Roberge, {Jacques Y.} and David Augeri and Tumer, {Nilgun E.}",
note = "Funding Information: We thank Stephanie P. Delatola and Arly Volmar for help with the in vitro depurination assay used in screening. We thank Dr. Chhaya Dharia for purifying RTA, Dr. John McLaughlin for statistical analysis, and Dr. Przemek Grela for Figure 1A. Research support was provided by NIH research grant AI072425 to Nilgun E. Tumer and NIH research grant GM041916 to Vern L. Schramm, Albert Einstein College of Medicine. We thank V.L.S. for advice and editing the manuscript. The School of Environmental and Biological Sciences (SEBS) Biomolecular Interaction Analysis Core Facility is supported by NIH Shared Instrumentation Grant S10 OD026750, which we gratefully acknowledge. The Einstein Crystallographic Core X-Ray diffraction facility is supported by NIH Shared Instrumentation Grant S10 OD020068, which we gratefully acknowledge. This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract DE-AC02-06CH11357. Use of the Lilly Research Laboratories Collaborative Access Team (LRL-CAT) beamline at Sector 31 of the Advanced Photon Source was provided by Eli Lilly Company, which operates the facility. Publisher Copyright: {\textcopyright} 2021 American Chemical Society.",
year = "2021",
month = oct,
day = "28",
doi = "10.1021/acs.jmedchem.1c01370",
language = "English (US)",
volume = "64",
pages = "15334--15348",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "20",
}